ATE78262T1 - Hybrid-interferone. - Google Patents

Hybrid-interferone.

Info

Publication number
ATE78262T1
ATE78262T1 AT86810243T AT86810243T ATE78262T1 AT E78262 T1 ATE78262 T1 AT E78262T1 AT 86810243 T AT86810243 T AT 86810243T AT 86810243 T AT86810243 T AT 86810243T AT E78262 T1 ATE78262 T1 AT E78262T1
Authority
AT
Austria
Prior art keywords
interferons
hybrid interferons
novel hybrid
hybrid
interferon
Prior art date
Application number
AT86810243T
Other languages
English (en)
Inventor
Francois Meyer
Albert Hinnen
Andreas Meister
Markus G Gruetter
Sefik Alkan
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE78262T1 publication Critical patent/ATE78262T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT86810243T 1985-06-11 1986-06-05 Hybrid-interferone. ATE78262T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
EP86810243A EP0205404B1 (de) 1985-06-11 1986-06-05 Hybrid-Interferone

Publications (1)

Publication Number Publication Date
ATE78262T1 true ATE78262T1 (de) 1992-08-15

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86810243T ATE78262T1 (de) 1985-06-11 1986-06-05 Hybrid-interferone.

Country Status (20)

Country Link
US (2) US4885166A (de)
EP (1) EP0205404B1 (de)
JP (2) JPH0655759B2 (de)
KR (1) KR920002267B1 (de)
AT (1) ATE78262T1 (de)
AU (1) AU598196B2 (de)
CA (1) CA1285507C (de)
CY (1) CY1842A (de)
DE (1) DE3685996T2 (de)
DK (1) DK168794B1 (de)
FI (1) FI90983C (de)
GR (1) GR861497B (de)
HK (1) HK99895A (de)
HU (1) HU203255B (de)
IE (1) IE57865B1 (de)
IL (1) IL79085A (de)
NO (1) NO175602C (de)
NZ (1) NZ216485A (de)
PT (1) PT82736B (de)
SG (1) SG25195G (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (de) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DK0548012T3 (da) * 1991-12-16 1998-04-14 Ciba Geigy Ag Endoplasmatisk reticulum-placeret rekombinant dibasisk endoprotease samt dens anvendelse
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0584343B1 (de) * 1992-03-10 1999-01-20 La Jolla Cancer Research Foundation Rekombinierte alkalische phosphatase aus kälberdarm
TW218846B (de) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (de) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
AU707657B2 (en) 1995-02-09 1999-07-15 Behringwerke Aktiengesellschaft Process for the production of proteins
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
BR0115392A (pt) 2000-11-03 2004-06-15 Biomedicines Inc Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2004046365A2 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7318918B2 (en) 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2006004959A2 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
DK2634242T3 (en) 2006-07-14 2017-05-22 Patheon Holdings I B V IMPROVED PROCEDURE FOR CULTURING CELLS
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
EP2712930A3 (de) 2006-12-06 2014-04-23 MedImmune, LLC Interferon-alpha-induzierte pharmakodynamische Marker
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2076533B1 (de) * 2007-05-02 2014-10-08 Ambrx, Inc. Modifizierte interferon-beta-polypeptide und ihre verwendungen
AU2008247398B2 (en) 2007-05-03 2013-10-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
PL2219452T3 (pl) 2007-11-05 2016-04-29 Medimmune Llc Sposoby leczenia twardziny
CA2714410A1 (en) 2008-02-08 2009-08-13 Medimmune, Llc Disease markers and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
EP3735944A1 (de) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SMT201800221T1 (it) 2011-03-15 2018-07-17 Biogen Ma Inc Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
BR112021015596A2 (pt) 2019-02-15 2021-10-05 Astrazeneca Ab Distúrbios mediados pelo interferon tipo i
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032134B2 (de) * 1980-01-08 1993-10-13 Biogen, Inc. DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von dem menschlichen Interferon-alpha ähnlichen Polypeptiden
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
EP0098876A1 (de) * 1982-01-19 1984-01-25 Cetus Corporation Hybrid-interferone verschiedener klassen
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
EP0173935A1 (de) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid-Lymphoblastoid-Leukozyten-Humaninterferone
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons

Also Published As

Publication number Publication date
IE861542L (en) 1986-12-11
DK168794B1 (da) 1994-06-13
NO175602C (no) 1994-11-02
DK272986A (da) 1986-12-12
JPS626000A (ja) 1987-01-12
PT82736B (pt) 1988-12-15
AU5849986A (en) 1986-12-18
DK272986D0 (da) 1986-06-10
JPH0655759B2 (ja) 1994-07-27
FI90983B (fi) 1994-01-14
NO862313L (no) 1986-12-12
FI862461L (fi) 1986-12-12
SG25195G (en) 1995-08-18
AU598196B2 (en) 1990-06-21
FI862461A0 (fi) 1986-06-09
FI90983C (fi) 1994-04-25
NO862313D0 (no) 1986-06-10
PT82736A (en) 1986-07-01
HUT41846A (en) 1987-05-28
DE3685996T2 (de) 1993-01-14
HK99895A (en) 1995-06-30
KR870000427A (ko) 1987-02-18
EP0205404A2 (de) 1986-12-17
EP0205404B1 (de) 1992-07-15
IE57865B1 (en) 1993-05-05
HU203255B (en) 1991-06-28
IL79085A (en) 1992-03-29
EP0205404A3 (en) 1987-10-21
GR861497B (en) 1986-10-10
US5071761A (en) 1991-12-10
DE3685996D1 (de) 1992-08-20
NO175602B (no) 1994-07-25
NZ216485A (en) 1991-06-25
CA1285507C (en) 1991-07-02
JPH05308973A (ja) 1993-11-22
KR920002267B1 (ko) 1992-03-20
US4885166A (en) 1989-12-05
IL79085A0 (en) 1986-09-30
CY1842A (en) 1996-03-08
JPH0736757B2 (ja) 1995-04-26

Similar Documents

Publication Publication Date Title
ATE78262T1 (de) Hybrid-interferone.
DE3583521D1 (de) Antivirale verbindungen.
IT8124967A0 (it) Interferoni di leucociti umani ibridi.
FI870377A7 (fi) Viruksenvastaisia koostumuksia.
FR2431507A1 (fr) 1-desamino-2-desoxy-2-epi-amino fortimicine b
FI873593L (fi) Nya applikationsformer foer -interferon.
DE3577713D1 (de) Thermoplastische, weichmacherhaltige polyvinylbutyralformmassen.
IT8620153A0 (it) 5-pririmidincarbossammidi per il trattamento di leucemia e tumori con le stesse.
NO873389L (no) Homogent rekombinant immun-interferon-fragment.
DE3575435D1 (de) Sinterfaehige, feinteilige formmasse auf basis von vinylchlorid-polymerisaten.
NO861635L (no) Fremgangsmaate for fremstilling av rekombinert aaa-interferon.
GB2168355B (en) Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
FI930024A0 (fi) Nya antivirala tetrahydroimidazo(1,4)benzodiazepin-2-(ti)oner
NO894573L (no) Rekombinante interleukin-2 hybridproteiner.
FI841787L (fi) Nya vektorer foer expression av interferon.
FI865128A0 (fi) Nya 16,17-acetalsubstituerade pregnan-21-karboxylsyraderivat.
FI853307A7 (fi) Ihmisen lymfoblastoidi -leukosyyttihydridi-interferoneja.
ATA551881A (de) Dreilagiger formkoerper, insbesondere blech, von hoher verschleissfestigkeit
DE3788225D1 (de) Steigerung der zellularen immunreaktion.
SU939352A1 (ru) Двухмассный вибрационный конвейер
ES2052562T3 (es) Peptido antineoplasico inducido por la interleucina-2.
DE3783697D1 (de) Antitumor-verbindungen.
ATE98263T1 (de) Immunverstaerkung.
LT2393B (lt) Mesos produkto, atgaminancio mesos struktura, gavimo budas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time